These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Pavel-Dinu M; Wiebking V; Dejene BT; Srifa W; Mantri S; Nicolas CE; Lee C; Bao G; Kildebeck EJ; Punjya N; Sindhu C; Inlay MA; Saxena N; DeRavin SS; Malech H; Roncarolo MG; Weinberg KI; Porteus MH Nat Commun; 2019 Apr; 10(1):1634. PubMed ID: 30967552 [TBL] [Abstract][Full Text] [Related]
5. Gene therapy for SCID-X1: focus on clinical data. Baum C Mol Ther; 2011 Dec; 19(12):2103-4. PubMed ID: 22134740 [No Abstract] [Full Text] [Related]
6. Advancing gene targeting for primary immune deficiencies: Adenine base editing of the human IL2RG locus for correction of SCID-X1. McIvor RS; Eaton EJ; Webber BR; Moriarity BS Mol Ther; 2024 Jun; 32(6):1606-1608. PubMed ID: 38781958 [No Abstract] [Full Text] [Related]
7. Toward Clinical Translation of New Gene Targeting Technologies for Correcting Inherited Mutations and Empowering Adoptive Immunotherapy of Cancer (SUPERSIST). Hum Gene Ther Clin Dev; 2015 Jun; 26(2):95-7. PubMed ID: 26086760 [No Abstract] [Full Text] [Related]
8. Restoring T and B cell generation in X-linked severe combined immunodeficiency mice through hematopoietic stem cells adenine base editing. Zhang L; Li K; Liu Z; An L; Wei H; Pang S; Cao Z; Huang X; Jin X; Ma X Mol Ther; 2024 Jun; 32(6):1658-1671. PubMed ID: 38532630 [TBL] [Abstract][Full Text] [Related]
9. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector. Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961 [TBL] [Abstract][Full Text] [Related]
10. Correction of SCID-X1 using an enhancerless Vav promoter. Almarza E; Zhang F; Santilli G; Blundell MP; Howe SJ; Thornhill SI; Bueren JA; Thrasher AJ Hum Gene Ther; 2011 Mar; 22(3):263-70. PubMed ID: 20887212 [TBL] [Abstract][Full Text] [Related]
11. Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency. Cuvelier GD; Schultz KR; Davis J; Hirschfeld AF; Junker AK; Tan R; Turvey SE Clin Immunol; 2009 May; 131(2):179-88. PubMed ID: 19217351 [TBL] [Abstract][Full Text] [Related]
12. Case Report: A Novel IL2RG Frame-Restoring Rescue Mutation Mimics Early T Cell Engraftment Following Haploidentical Hematopoietic Stem Cell Transplantation in a Patient With X-SCID. Steininger J; Leiss-Piller A; Geier CB; Rossmanith R; Elfeky R; Bra D; Pichler H; Lawitschka A; Zubarovskaya N; Artacker G; Matthes-Leodolter S; Eibl MM; Wolf HM Front Immunol; 2021; 12():644687. PubMed ID: 33959125 [TBL] [Abstract][Full Text] [Related]
13. T-cell-replete haploidentical bone marrow transplantation for X-linked severe combined immunodeficiency. Ariffin H; Chew KS; Jawin V; Thavagnanam S Singapore Med J; 2020 May; 61(5):284-285. PubMed ID: 30128577 [No Abstract] [Full Text] [Related]
14. Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1. Touzot F; Moshous D; Creidy R; Neven B; Frange P; Cros G; Caccavelli L; Blondeau J; Magnani A; Luby JM; Ternaux B; Picard C; Blanche S; Fischer A; Hacein-Bey-Abina S; Cavazzana M Blood; 2015 Jun; 125(23):3563-9. PubMed ID: 25869287 [TBL] [Abstract][Full Text] [Related]
15. Genome editing: a tool for research and therapy: targeted genome editing hits the clinic. Lombardo A; Naldini L Nat Med; 2014 Oct; 20(10):1101-3. PubMed ID: 25295939 [No Abstract] [Full Text] [Related]
17. Targeted genome editing in human repopulating haematopoietic stem cells. Genovese P; Schiroli G; Escobar G; Tomaso TD; Firrito C; Calabria A; Moi D; Mazzieri R; Bonini C; Holmes MC; Gregory PD; van der Burg M; Gentner B; Montini E; Lombardo A; Naldini L Nature; 2014 Jun; 510(7504):235-240. PubMed ID: 24870228 [TBL] [Abstract][Full Text] [Related]
18. New Gene Therapy Potential Cure for "Bubble Boy Disease": An experimental gene therapy has allowed children with SCID-1X to develop fully functioning immune systems. Am J Med Genet A; 2019 Jul; 179(7):1114-1115. PubMed ID: 31180192 [No Abstract] [Full Text] [Related]
19. Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency. Speckmann C; Pannicke U; Wiech E; Schwarz K; Fisch P; Friedrich W; Niehues T; Gilmour K; Buiting K; Schlesier M; Eibel H; Rohr J; Superti-Furga A; Gross-Wieltsch U; Ehl S Blood; 2008 Nov; 112(10):4090-7. PubMed ID: 18728247 [TBL] [Abstract][Full Text] [Related]